Total Payments
$47,907
2024 Payments
$24,947
Companies
25
Transactions
167
Medicare Patients
3,555
Medicare Billing
$698,492
Payment Breakdown by Category
Other$30,550 (63.8%)
Travel$8,866 (18.5%)
Food & Beverage$4,103 (8.6%)
Consulting$4,100 (8.6%)
Education$288.35 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $30,550 | 17 | 63.8% |
| Travel and Lodging | $8,866 | 8 | 18.5% |
| Food and Beverage | $4,103 | 131 | 8.6% |
| Consulting Fee | $4,100 | 2 | 8.6% |
| Education | $288.35 | 9 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CALLIDITAS THERAPEUTICS US INC. | $44,312 | 39 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $561.83 | 16 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $490.75 | 9 | $0 (2023) |
| Novo Nordisk Inc | $290.25 | 18 | $0 (2024) |
| AKEBIA THERAPEUTICS INC | $220.98 | 11 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $193.60 | 7 | $0 (2024) |
| Travere Therapeutics, Inc. | $184.72 | 5 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $169.13 | 7 | $0 (2024) |
| Aurinia Pharma U.S., Inc. | $142.77 | 8 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $139.85 | 8 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,947 | 36 | CALLIDITAS THERAPEUTICS US INC. ($24,385) |
| 2023 | $17,410 | 45 | Calliditas Therapeutics US Inc. ($16,292) |
| 2022 | $4,117 | 28 | CALLIDITAS THERAPEUTICS US INC. ($3,634) |
| 2021 | $338.98 | 18 | Mallinckrodt Hospital Products Inc. ($111.09) |
| 2020 | $157.94 | 8 | Novo Nordisk Inc ($39.21) |
| 2019 | $424.80 | 16 | Otsuka America Pharmaceutical, Inc. ($120.88) |
| 2018 | $288.21 | 5 | BioDelivery Sciences International, Inc. ($121.87) |
| 2017 | $223.53 | 11 | Novartis Pharmaceuticals Corporation ($87.81) |
All Payment Transactions
167 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $26.43 | General |
| Category: IMMUNOLOGY | ||||||
| 12/20/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $10.61 | General |
| Category: Nephrology | ||||||
| 12/19/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Honoraria | Cash or cash equivalent | $2,700.00 | General |
| Category: Nephrology | ||||||
| 12/13/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $23.69 | General |
| Category: NEPHROLOGY | ||||||
| 12/12/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Honoraria | Cash or cash equivalent | $3,100.00 | General |
| Category: Nephrology | ||||||
| 12/12/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Travel and Lodging | Cash or cash equivalent | $1,779.40 | General |
| Category: Nephrology | ||||||
| 12/12/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $112.50 | General |
| Category: Nephrology | ||||||
| 12/09/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Honoraria | Cash or cash equivalent | $800.00 | General |
| Category: Nephrology | ||||||
| 12/06/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Education | In-kind items and services | $24.61 | General |
| Category: Nephrology | ||||||
| 12/04/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $116.47 | General |
| Category: Nephrology | ||||||
| 11/26/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Honoraria | Cash or cash equivalent | $2,400.00 | General |
| Category: Nephrology | ||||||
| 11/22/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $15.86 | General |
| Category: Obesity | ||||||
| 11/01/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Nephrology | ||||||
| 10/26/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $48.45 | General |
| Category: Nephrology | ||||||
| 10/23/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological), NUCALA | Food and Beverage | In-kind items and services | $29.38 | General |
| Category: IMMUNOLOGY | ||||||
| 10/09/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Education | In-kind items and services | $24.61 | General |
| Category: Nephrology | ||||||
| 09/30/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: Obesity | ||||||
| 09/28/2024 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Food and Beverage | In-kind items and services | $17.11 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 09/26/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Honoraria | Cash or cash equivalent | $2,800.00 | General |
| Category: Nephrology | ||||||
| 09/26/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Honoraria | Cash or cash equivalent | $2,650.00 | General |
| Category: Nephrology | ||||||
| 09/19/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Travel and Lodging | Cash or cash equivalent | $1,524.88 | General |
| Category: Nephrology | ||||||
| 09/19/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: Nephrology | ||||||
| 09/17/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Travel and Lodging | Cash or cash equivalent | $1,791.35 | General |
| Category: Nephrology | ||||||
| 09/17/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $26.32 | General |
| Category: Nephrology | ||||||
| 08/30/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $24.74 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 733 | 1,546 | $363,076 | $129,881 |
| 2022 | 14 | 1,102 | 2,291 | $470,159 | $194,959 |
| 2021 | 14 | 930 | 2,279 | $526,275 | $203,154 |
| 2020 | 14 | 790 | 1,764 | $452,925 | $170,499 |
Total Patients
3,555
Total Services
7,880
Medicare Billing
$698,492
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 280 | 622 | $155,500 | $50,156 | 32.3% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 16 | 83 | $58,100 | $20,134 | 34.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 99 | 146 | $43,800 | $10,917 | 24.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 50 | 68 | $20,400 | $9,687 | 47.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 28 | 87 | $21,750 | $8,709 | 40.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 61 | 61 | $21,350 | $8,277 | 38.8% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 67 | 170 | $8,330 | $5,746 | 69.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 81 | $14,175 | $5,495 | 38.8% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 53 | 145 | $7,975 | $5,260 | 66.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 19 | 19 | $7,600 | $3,328 | 43.8% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 29 | 64 | $4,096 | $2,170 | 53.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 166 | 307 | $92,100 | $45,327 | 49.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 273 | 451 | $112,750 | $43,504 | 38.6% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 14 | 75 | $45,000 | $19,123 | 42.5% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 114 | 430 | $46,421 | $16,329 | 35.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 66 | 79 | $23,700 | $12,637 | 53.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 46 | 131 | $32,750 | $11,207 | 34.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 48 | 178 | $31,150 | $10,437 | 33.5% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 69 | 213 | $21,165 | $9,126 | 43.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 45 | 45 | $18,000 | $8,134 | 45.2% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2022 | 84 | 140 | $8,960 | $7,042 | 78.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 55 | 55 | $19,250 | $6,672 | 34.7% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2022 | 29 | 77 | $13,205 | $2,490 | 18.9% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 11 | 27 | $4,050 | $1,705 | 42.1% |
| 99453 | Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | Office | 2022 | 82 | 83 | $1,658 | $1,225 | 73.9% |
About Dr. Neeraja Tandra, MD
Dr. Neeraja Tandra, MD is a Nephrology healthcare provider based in Reston, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1821201385.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Neeraja Tandra, MD has received a total of $47,907 in payments from pharmaceutical and medical device companies, with $24,947 received in 2024. These payments were reported across 167 transactions from 25 companies. The most common payment nature is "Honoraria" ($30,550).
As a Medicare-enrolled provider, Tandra has provided services to 3,555 Medicare beneficiaries, totaling 7,880 services with total Medicare billing of $698,492. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Reston, VA
- Active Since 05/08/2007
- Last Updated 12/27/2021
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1821201385
Products in Payments
- TARPEYO (Drug) $44,312
- ACTHAR (Biological) $700.80
- Veltassa (Drug) $213.36
- Auryxia (Drug) $181.95
- Ozempic (Drug) $178.50
- LUPKYNIS (Drug) $142.77
- JYNARQUE (Drug) $132.40
- BELBUCA (Drug) $121.87
- Parsabiv (Biological) $121.39
- Kerendia (Drug) $118.27
- QULIPTA (Drug) $113.91
- LOKELMA (Drug) $103.67
- Diamondback Peripheral (Device) $94.74
- AFINITOR (Drug) $92.97
- SAMSCA (Drug) $61.20
- Rayaldee (Drug) $59.33
- ULTOMIRIS (Biological) $58.47
- Wegovy (Drug) $49.96
- Vafseo (Drug) $49.22
- Rybelsus (Drug) $46.14
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.